Credit Suisse Ag Intra Cellular Therapies, Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
A detailed history of Credit Suisse Ag transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 124,596 shares of ITCI stock, worth $10.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
124,596
Previous 118,582
5.07%
Holding current value
$10.8 Million
Previous $8.49 Million
1.53%
% of portfolio
0.01%
Previous 0.01%
Shares
28 transactions
Others Institutions Holding ITCI
# of Institutions
378Shares Held
84.7MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$832 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$546 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$457 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$333 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$264 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $8.16B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...